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1. Introduction
  Organ transplants were carried out gradually in recent 
years, but the postoperative autologous immune rejection 
become the most thorny problem[1-5]. Efficient immune 
inhibitor combined application can reduce the incidence of 
rejection after transplantation, obviously prolong survival 
time after transplantation[6-10]. The human body has the 
same reactive T cells of CD4+ CD25+ regulatory T cells 
(Tregs), it was showed that regulatory T cells content of 
the patients with immunosuppressant can be changed 
after transplantation[11-16]. Rapamycin (SRL) are one of 
macrolides families, studies have shown that SRL has 
stronger immune inhibition effect, which was widely used 
in the treatment of kidney transplant rejection[17-24]. The 
author aims to observe its influence on regulate T cell’s 
activation and function, SRL lavage was used on SD rats to 
observe its regulatory effect on CD4+, CD25+, FoxP3+ T cells, 
the results are reported as follows.
2. Materials and methods 
2.1. Experimental animals
  A total of 40 SD rats were selected, only our animal 
experiment center, clean level, male, weighting 210-220 g,
aged 8 to 10 weeks, the rats were fed free with food and 
water, animal in the experimental were processed strictly 
according to the administration of experimental animals.
2.2. Instrument and preparation
  Real time PCR instrument, FACS Aria TM flow cytometry 
instrument (BD co., United States); TGF-beta and IL-
10 ELISA kit, RT-PCR kit (TaKaRa); Sirolimus (Wyeth 
Pharmaceutical co., LTD.)-the White House. Hemolysin, 
collagenase and hyaluronidase, Trizol reagent (Invitrogen 
Company). RPMI-1640 medium, PE-conjugated anti-CD25, 
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APC-conjugated anti-CD4 (eBioscience co. US).
2.3. Methods 
  A total of 40 rats were randomly divided into experimental 
group and control group with 20 in each, the experimental 
group rats were given SRL lavage (0.4 mg/d) for 2 weeks; the 
control group given were given the same volume of saline 
lavage for 2 weeks. Pentobarbital was used for anesthesia 
(ip.), inferior vena venous blood was extracted for further 
use; Rats spleen and thymus were grinded using 200 mesh 
metal filter, for preparation of 106 cells/mL suspension cells 
using RPMI-1640.
2.4. Observe project
  A total of 100 毺L spleen cells , thymus suspension and 
heparin anticoagulant was absorbed respectively, adding
1 毺L APC-conjugatedanti-CD4 (0.25 毺L), LPE-conjugated 
anti-CD2, incubated away from light for 15 min, hemolysin, 
centrifugal 5 min, abandon supernatant, PBS wash twice, 
plus 200 毺L PBS blending, computer detection of CD4+ 
CD25+ T cells accounted for the proportion of mononuclear 
cells; with double antibody sandwich ELISA method to 
detect the rat TGF-beta and IL-10 in serum level; and the 
real-time PCR kits in the spleen cell SAP FoxP3 mRNA 
expression. The experiment was performed strictly in 
accordance with the above instructions.
2.5. Statistical processing
  Using SPSS12.0 statistics software to process the experiment 
data, measurement data are expressed with (x依s), group 
comparision was analysed by t test, P<0.05 for the difference 
was statistically significant.
3. Results
3.1. CD4+ and CD25+ T cells detection in the peripheral 
blood, thymus and spleen
  The experimental group in the peripheral blood, spleen 
and thymus of CD4+ and CD25+ T cells accounted for the 
proportion of mononuclear cells are higher than the control 
group with statistically significant (P<0.05), the results are 
shown in Table 1.
3.2. Level of TGF-毬, IL-10 in serum
  Experimental rats serum TGF-毬, IL-10 were significantly 
higher than that of control group (P<0.05), as shown in Figure 
1.
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Figure 1. Level of TGF-毬, IL-10 in serum. *P<0.05 compare with 
control group.
3.3. AP FoxP3 mRNA expression comparison in two groups
  Experimental rats spleen FoxP3 mRNA was significantly 
higher than that of control group (P<0.05), as shown in Figure 
2.
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Figure 2. SAP FoxP3 mRNA expression comparison in two groups.
4. Discussion
  CD4+ T cells were discovered in the thymus by Sakaguchi 
et al. in the 90 s, the new borne rats which accepted the 
thymus excision (d3Tx) injection of CD4+ CD25+ T cells can 
prevent autoimmune diseases[25-29]. The current universal 
view is that thymus is able to produce CD4+ CD25+ T in 
peripheral blood[30]. Studies have shown that[31-34], CD4+ and 
Table 1
CD4+ and CD25+ T cells detection in the peripheral blood, thymus and spleen (%).
Groups n Peripheral blood Thymus Spleen
Experimental group 20   9.18依3.48* 20.39依4.90* 14.55依3.59*
Control group 20 5.35依1.36  8.31依2.56  6.69依2.63
*P<0.05 compare with control group.
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CD25+ T cells can prevent autoimmune reactions and tissue 
damage caused by rejection and inflammatory response after 
organ transplantation.
  Sirolimus is a potent immune inhibitor, has been 
widely applied in the immune rejection after kidney 
transplantation[35]. It works mainly by inhibiting the antigens 
and cytokines stimulation of T lymphocyte activation 
and proliferation of immune inhibition[36]. Sirolimus can 
selectively amplify CD4+ CD25+ and FoxP3+ T cells without 
blocking the CD4+ T cell expansion and activation to induce 
cell apoptosis[37]. CD4+ CD25+ and FoxP3+ regulatory T cells 
play an important role in maintaining immune tolerance. 
Studies have shown that[38-40], sirolimus can induce 
immune inhibition of regulatory T cells. In this study, the 
experimental group to sirolimus lavage (0.4 mg/d) after 2 
weeks, the experimental group rats an increasing CD4+ 
CD25+ T cells proportion of mononuclear cells in peripheral 
blood, thymus and spleen significantly, much higher than 
that of control group (P<0.05); and the experimental group 
rats spleen foxp3 mRNA expression, TGF-beta, IL-10 levels 
were significantly higher than the control group (P<0.05), 
indicating that sirolimus can induce rats in vivo CD4+ CD25+ 
FoxP3+ regulatory T cell proliferation, leading to immune 
rejection tolerance.
  According to the results of this study, immune inhibitors 
can increase the rat proportion of CD4+ CD25+ and FoxP3+ 
regulatory T cells in the mononuclear cells in vivo, shows 
that it can induce proliferation of CD4+ CD25+ and FoxP3+ 
regulatory T cells in rats, so it can play an important role in 
maintaining immune tolerance.
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